Infanrix Hexa, 0.5 ml syringe

Infantrix complies with WHO requirements for the production of biologics and vaccines against diphtheria, tetanus and pertussis.

One month after the three-dose course of initial Infantrix vaccination in the first months of life, more than 99% of children immunized with Infantrix vaccine have antibody titers to diphtheria and tetanus anatoxins greater than 0.1 IU/ml.
Antibodies to pertussis antigens (CA, FHA and pertactin) are produced in more than 95% of vaccinated children.

After revaccination with Infantrix vaccine in the second year of life (13 to 24 months), all children who were initially immunized with Infantrix vaccine have antibody titers of more than 0.1 IU/ml for diphtheria and tetanus toxoids.

The secondary immune response to pertussis antigens occurs in more than 96% of children.

The protective efficacy of the Infanrix vaccine reaches an average of 88%.

Indications

How to take, the dosage

The primary vaccination course consists of three vaccine doses administered according to the Russian National Preventive Vaccination Calendar at 3, 4, 5 and 6 months of age; revaccination is carried out at 18 months of age.

Before vaccination the vaccine is shaken well until a homogeneous turbid suspension is formed and examined carefully. If foreign particles, unbreakable flakes or changes in appearance are found, the vaccine should not be used.

Infantrix vaccine should be given by intramuscular injection and alternate sites during the course of the vaccination.

The vaccine should never be given intravenously!

Interaction

Special Instructions

Contraindications

Side effects